Aura Biosciences price target raised to $25 from $22 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm’s price target on Aura Biosciences (AURA) to $25 from $22 and keeps a Buy rating on the shares following the Q4 report. The Phase 3 CoMpass trial in early-stage choroidal melanoma is actively enrolling, the analyst tells investors in a research note.